MONOCLONAL-ANTIBODIES REACTIVE WITH HUMAN MYELOID-LEUKEMIA CELLS

  • 1 January 1982
    • journal article
    • research article
    • Vol. 48  (3) , 655-665
Abstract
Mouse hybridomas producing monoclonal antibodies that bind to determinants on myelogenous leukemia blast cells were developed using fresh leukemia blasts as immunogens. These monoclonal antibodies were used to quantitate the amount of a variety of antigens on both leukemia and normal blood cells in a radioimmunoassay. The ability of these antibodies to mediate complement-dependent lysis of leukemia cells and normal blood cells was evaluated. Significant quantitative differences in the expression of a variety of cell surface antigens were observed among different myeloid leukemia cell samples, normal cells and other forms of leukemia. None of the monoclonal antibodies studied were found to be specific for myeloblasts. Despite the fact that these antibodies bound to both leukemia and normal cells, several of them mediated complement-dependent cytotoxicity which was restricted to leukemic myeloblasts (AML-1-211, AML-2-30, CML-18, CML-75, CL-115 and CML-150). None of these clones, alone or in any combination, were capable of lysing normal lymphocytes or monocytes. Others were specifically cytotoxic to leukemia cell lines (AML-1-99), B cells and some leukemia samples (AML-2-9), and myelomonocytic leukemia cell samples and normal monocytes (AML-2-23). Several of the monoclonal antibodies from this panel appear to be promising for future clinical applications.